The Effect of N2O on Chronic Neuropathic Pain Patients
Unknown statusEarly phase 1NCT02246517
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Important pharmacological agents for treatment of chronic neuropathic pain such as ketamine block NMDA receptors. Nitrous oxide, an inhalant agent used extensively In anesthesia, also have antagonist property of NMDA receptors. The investigators hypothesize that prolonged treatment with N2O can alleviate chronic neuropathic pain of different causes (e.g. diabetic neuropathy, post herpetic neuralgia etc.).
Study details
- Official title
- The Effect of N2O on Chronic Neuropathic Pain
- Conditions
- Interventions
- Drug: N2O
- Drug: Oxygen
- Sponsor
- Tel-Aviv Sourasky Medical Center
- Start date
- 2014-09
- Primary completion
- 2015-12
- Sex
- All
- Age range
- from 18 Years to 65 Years
- Results posted
- No results posted in this snapshot
- Countries
- Israel
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * men and women at the age 18-65 * patient that suffer from chronic neuropathic pain * VAS\>40 * DN4 score \>4 * takes pain medication on a regular basis * Didn't get epidural injection for the pas month * signed an informed consent form Exclusion Criteria: * patients that suffer from chronic lung disease. * patients with cancer * patients with heart disease * pregnant and lactate woman * patients that suffer from depression
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT02246517